FS Development Corp. II (FSII) Social Stream
Featured Post From StockTwits About FSII
$FSII Not yet in the clinic, Pardes Bio’s Covid-19 pill still fills in Foresite’s blank checkStrategyDD, published August 8, 2021
Pardes Biosciences advanced from concept to drug candidate in less than nine months. The preclinical biotech is developing an oral antiviral for Covid-19 and other coronavirus infections and it is going public in a SPAC merger that will infuse it with $276 million.
https://medcitynews.com/2021/06/not-yet-in-the-clinic-pardes-bios-covid-19-pill-still-fills-in-foresites-blank-check/
Loading social stream, please wait...